TRPM3 and myalgic encephalomeyelitis/chronic fatigue syndrome: In ME/CFS, there is clear evidence of a loss-of-function mutation in TRPM3, as indicated by decreased calcium influx, which can be improved by low-dose naltrexone (LDN) treatment [16].